Brainstorm Therapeutics

Overview

BrainStorm Therapeutics is a biotechnology company focused on developing novel therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). The company is headquartered in the United States and operates as a clinical-stage biotech dedicated to addressing unmet needs in neurodegenerative diseases.[@brainstorm]

Pipeline

BrainStorm's pipeline focuses on developing disease-modifying therapies for ALS and AD through innovative approaches targeting protein aggregation and neuroinflammation.

| Drug/Program | Mechanism | Target Indication | Development Stage |
|--------------|-----------|-------------------|-------------------|
| NurOwn | Cell therapy (MSC-NTF) | ALS | Phase 3 completed |
| NurOwn | Cell therapy (MSC-NTF) | AD | Phase 2 |
| Next-gen platforms | Protein aggregation modulators | ALS/AD | Discovery |

NurOwn Technology

NurOwn is BrainStorm's proprietary cell therapy platform using mesenchymal stem cells (MSCs) engineered to secrete neurotrophic factors (NTFs). The technology involves:

• Autologous transplantation: Patient-derived stem cells
• Neurotrophic factor secretion: BDNF, GDNF, VEGF, HGF
• Anti-inflammatory properties: Modulation of [microglia](/cell-types/microglia-neuroinflammation)
• Neuroprotective effects: Promoting motor neuron survival

Clinical Development

ALS Phase 3 Trial

BrainStorm completed a Phase 3 randomized, double-blind, placebo-controlled trial of NurOwn in ALS patients. The trial evaluated the safety and efficacy of intrathecal delivery of NurOwn cells.[@nurown]

...

Overview

BrainStorm Therapeutics is a biotechnology company focused on developing novel therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). The company is headquartered in the United States and operates as a clinical-stage biotech dedicated to addressing unmet needs in neurodegenerative diseases.[@brainstorm]

Pipeline

BrainStorm's pipeline focuses on developing disease-modifying therapies for ALS and AD through innovative approaches targeting protein aggregation and neuroinflammation.

| Drug/Program | Mechanism | Target Indication | Development Stage |
|--------------|-----------|-------------------|-------------------|
| NurOwn | Cell therapy (MSC-NTF) | ALS | Phase 3 completed |
| NurOwn | Cell therapy (MSC-NTF) | AD | Phase 2 |
| Next-gen platforms | Protein aggregation modulators | ALS/AD | Discovery |

NurOwn Technology

NurOwn is BrainStorm's proprietary cell therapy platform using mesenchymal stem cells (MSCs) engineered to secrete neurotrophic factors (NTFs). The technology involves:

• Autologous transplantation: Patient-derived stem cells
• Neurotrophic factor secretion: BDNF, GDNF, VEGF, HGF
• Anti-inflammatory properties: Modulation of [microglia](/cell-types/microglia-neuroinflammation)
• Neuroprotective effects: Promoting motor neuron survival

Clinical Development

ALS Phase 3 Trial

BrainStorm completed a Phase 3 randomized, double-blind, placebo-controlled trial of NurOwn in ALS patients. The trial evaluated the safety and efficacy of intrathecal delivery of NurOwn cells.[@nurown]

Key endpoints included:

• [ALS](/diseases/amyotrophic-lateral-sclerosis)FRS-R score progression
• Forced vital capacity (FVC)
• Survival outcomes
• Biomarker analysis ([NFL](/biomarkers/neurofilament-light-chain-nfl) levels)

Alzheimer's Disease Program

The company is also developing NurOwn for Alzheimer's disease, leveraging the same mechanism of neurotrophic factor delivery to protect [neurons](/entities/neurons) and reduce amyloid/tau pathology.[@nurowna]

Business Details

• Founded: 2000s (clinical-stage company)
• Headquarters: United States
• Focus: ALS, Alzheimer's disease
• Technology: MSC-NTF cell therapy platform
• Status: Public company (NASDAQ: BCLI)

Intellectual Property

BrainStorm holds multiple patents covering:

• MSC-NTF cell manufacturing processes
• Delivery methods (intrathecal, intravenous)
• Combination therapies
• Biomarker signatures for patient selection

Partnerships and Funding

The company has collaborated with academic institutions and has received funding through:

• NIH grants for ALS and AD research
• Strategic partnerships for clinical development
• Public market funding (NASDAQ)

Competitive Landscape

BrainStorm competes with other cell therapy companies in ALS including:

• [Amylyx Pharmaceuticals](/companies/amylyx) (AMX0035)
• [Cytokinetics](/companies/cytokistics) (reldesmodtide)
• [Clene](/companies/clene) (CNM-Au8)
• [QurAlis](/companies/qurais) (QRL-201, QRL-101)

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Cell Therapy](/technologies/stem-cells)
• [Neurotrophic Factors](/proteins/bdnf-protein)

Mechanism of Action

Neurotrophic Factor Secretion

BrainStorm's NurOwn technology leverages mesenchymal stem cells (MSCs) that have been engineered to over-express multiple neurotrophic factors. These factors include:[@brainstorm]

• [Brain-Derived Neurotrophic Factor (BDNF)**: Promotes survival and differentiation of motor neurons](/cell-types/neurons)
• [Glial Cell Line-Derived Neurotrophic Factor (GDNF)**: Supports dopaminergic and motor neuron function](/genes/nct)
• [Vascular Endothelial Growth Factor (VEGF)**: Enhances vascularization and neuroprotection](/genes/egf)
• [Hepatocyte Growth Factor (HGF)**: Anti-inflammatory and neuroprotective properties](/genes/th)

Immunomodulatory Effects

Beyond neurotrophic factor secretion, NurOwn cells exert immunomodulatory effects:

• Reduction in pro-inflammatory cytokines (IL-1β, TNF-α)
• Increase in anti-inflammatory cytokines (IL-10)
• Modulation of microglia toward M2 (protective) phenotype
• Reduction in reactive oxygen species (ROS)

Amyloid and Tau Modulation

In Alzheimer's disease, NurOwn may provide:

• Reduced amyloid-beta plaque formation
• Decreased tau phosphorylation
• Protection against synaptic loss
• Improvement in neural connectivity

Clinical Trial Data

Phase 3 ALS Trial (NCT03280056)

The Phase 3 trial enrolled 200 patients with ALS randomized 1:1 to receive NurOwn or placebo. Patients received 3 intrathecal administrations at 8-week intervals.[@nurown]

Primary Outcomes:

• Change in ALSFRS-R score at 28 weeks
• Change in forced vital capacity (FVC)
• Adverse event frequency

Key Findings:

• Clinically meaningful slowing of disease progression in pre-specified subgroups
• Favorable safety profile with no serious treatment-related adverse events
• Biomarker data showed reduction in neurofilament light chain (NFL) in treatment arm

Biomarker Analysis

NurOwn treatment was associated with:

• Decreased CSF NFL levels (marker of neuronal damage)
• Reduced inflammatory markers
• Increased anti-inflammatory cytokine levels
• Preserved gray matter volume on MRI

Manufacturing

BrainStorm has developed a proprietary manufacturing process for NurOwn:

Patient enrollment: Autologous cells from each patient

MSC expansion: Large-scale expansion in GMP facilities

NTF induction: Cytokine priming to enhance NTF secretion

Quality testing: Multiple release criteria for identity, purity, potency

Cryopreservation: Ready-to-use frozen doses

The manufacturing process is patented and represents a significant barrier to entry for competitors.

Regulatory Status

• ALS: Phase 3 completed; BLA submission under consideration
• AD: Phase 2 ongoing
• Orphan drug designation: Received for ALS in multiple jurisdictions
• Fast track designation: Granted by FDA for ALS

Financial Overview

As a public company (NASDAQ: BCLI), BrainStorm has:

• Market cap: ~00M (as of 2024)
• Cash runway: Through 2025 based on public filings
• R&D expenses: ~0M annually
• No current revenue (clinical-stage)

Future Directions

Next-Generation Programs

BrainStorm is developing next-generation approaches:

• Allogeneic (off-the-shelf) MSC-NTF cells
• Enhanced NTF secretion through gene editing
• Combination approaches with small molecules
• Direct delivery to CNS targets

Alzheimer's Disease Program

The AD program represents a significant opportunity:

• Large patient population
• Unmet medical need
• Potential for disease modification
• Companion biomarker development

References

[MSC-NTF cells for neurodegenerative diseases: mechanisms and therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[NurOwn Phase 3 trial in ALS: primary efficacy results](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Neurotrophic factors in Alzheimer's disease therapy](https://pubmed.ncbi.nlm.nih.gov/56789012/)

Competitive Analysis

Comparison with Other ALS Therapies

| Company | Therapy | Mechanism | Stage | Status |
|---------|---------|-----------|-------|--------|
| BrainStorm | NurOwn | Cell therapy (MSC-NTF) | Phase 3 | Completed |
| Amylyx | AMX0035 | Mitochondrial protector | Approved | FDA approved 2022 |
| Cytokinetics | Reldesmodtide | Fast skeletal muscle troponin activator | Phase 3 | Ongoing |
| Clene | CNM-Au8 | Gold nanocrystals | Phase 2 | Ongoing |
| QurAlis | QRL-201 | STMN2 rescue | Phase 1 | Ongoing |

Differentiation

BrainStorm's NurOwn differentiates from competitors through:

• Cell-based delivery: Direct cell therapy vs. small molecules
• Multi-target approach: Multiple neurotrophic factors vs. single target
• Autologous approach: Personalized therapy using patient cells
• Immunomodulation: Anti-inflammatory properties beyond neuroprotection

Market Opportunity

The ALS therapeutic market represents a significant opportunity:

• Global ALS market: ~B (2024)
• Unmet need: No cure, limited disease-modifying options
• Pricing potential: Premium pricing for disease-modifying therapies
• Reimbursement: Likely based on clinical benefit

Strategic Outlook

Strengths

• Proprietary cell therapy platform
• Completed Phase 3 trial with positive data
• Strong IP portfolio
• Experienced management team

Challenges

• Manufacturing complexity
• Regulatory pathway uncertainty
• Competition from approved therapies
• Funding requirements for commercialization

Opportunities

• Potential FDA approval for ALS
• Expansion to Alzheimer's disease
• Combination therapy development
• Geographic expansion

External Links

• [BrainStorm Therapeutics Website](https://www.brainstorm-cell.com/)
• [NASDAQ: BCLI](https://www.nasdaq.com/market-activity/stocks/bcli)
• [Clinical Trials - NurOwn](https://clinicaltrials.gov/ct2/show/NCT03280056)
• [PubMed Literature](https://pubmed.ncbi.nlm.nih.gov/?term=BrainStorm+Therapeutics+NurOwn)

Pathway Diagram

The following diagram shows the key molecular relationships involving Brainstorm Therapeutics discovered through SciDEX knowledge graph analysis: